ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 5

Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

November 30, 2023

Michael Postow, MD, John M. Kirkwood, MD, Meredith McKean, MD, MPH, Helen Moon, MD, Sapna Patel, BA, MD

Beyond symptoms, doctors consider the psychosocial factors impacting treatment access and adherence, like insurance coverage, cost, family support, and preexisting conditions, when deciding between immunotherapy and targeted therapy for patients with BRAF-mutated metastatic melanoma.

EP. 1: The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP. 2: Best Practices for Biomarker Testing in Metastatic Melanoma

EP. 3: Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP. 4: Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

Now Viewing

EP. 5: Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

EP. 6: Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 7: Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP. 8: Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 9: Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

EP. 10: Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

EP. 11: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases